April 15 (Bloomberg) -- A gap in U.S. patent law has kept cheap copies of Novartis AG's heart drug Diovan off the market for 18 months, costing U.S. consumers and insurers as much as $900 million in potential savings. While the Diovan patent ... Washington Post, 1 day ago
Ranbaxy's Woes Add $900 Million to U.S. Heart Drug Costs - Bloomberg, 2 days ago
Ranbaxy's woes add $900 million in costs for heart drug - Livemint.com, 2 days ago
3 images for "arun sawhney"
Ranbaxy Laboratories, set to be merged with Sun Pharmaceutical Industries, might again have to pay a hefty penalty to the US authorities for alleged violations at its Toansa factory in Punjab. The facility is currently banned from supplying products ...Business Standard India, 3 days ago
Indian pharmaceutical firm Ranbaxy Laboratories has struggled ever since its promoter family sold controlling interest in the company to Japan's Daiichi Sankyo in 2008. No one, however, expected the Japanese pharma major to give up the fight. In an ...Wharton, 5 days ago Sun Pharma buys Ranbaxy for $3.2b, turns it Indian again The Financial Chronicle, 1 week ago Sun Pharma buys Ranbaxy to create generics giant Livemint.com, 1 week ago Sun Pharma to buy Ranbaxy in $3.2B all-stock deal VC Circle, 1 week ago
DAIICHI SANKYO : Announcement Regarding Merger Between Sun Pharma and Daiichi Sankyo's Subsidiary Ranbaxy and Resulting Change in Subsidiary
For Immediate Release 2014.04.11 Company name: DAIICHI SANKYO COMPANY, LIMITED Representative: Joji Nakayama, President and CEO (Code no.: 4568, First Section, Tokyo Stock Exchange) Please address inquiries to Noriaki Ishida, Corporate ...4 Traders, 5 days ago Ranbaxy: Lessons and Opportunities PharmaceuticalProcessing, 6 days ago Top heads to roll soon at Ranbaxy Business Standard India, 1 week ago Sun Pharma to acquire Ranbaxy The Hindu, 1 week ago
Mumbai: On hindsight, which is always 20:20, the stock movement in the preceding week should have foretold the story. On Friday, 4 April, shares of Ranbaxy Laboratories Ltd rose 8.2% to Rs. 459.55 on BSE, taking the stock's weekly gain to 26%. ...Livemint.com, 6 days ago
NEW DELHI: A senior-level exit has taken place at Ranbaxy Laboratories, after Chairman Tsutomu Une, a veteran at Japanese parent Daiichi Sankyo, held an open house meeting to introspect on what went wrong with the company and who should be held ...Economic Times, 1 week ago Ranbaxy's TL Easwar quits post introspection Economic Times, 1 week ago
The move is seen as enhancing the company's global presence Sushmi Dey | New Delhi April 8, 2014 Last Updated at 00:25 IST Sun Pharma’s acquisition of Ranbaxy has once again revived evaluation of the troubled past of the latter, which had ...Business Standard India, 1 week ago
T 1: Achieving Compliance With the baggage of regulatory issues, the biggest challenge for Sun Pharma will be to restore and regain trust and confidence of the regulators, especially in the US. Four of Ranbaxy plants are banned by USFDA and is ...Moneycontrol.com, 1 week ago 5 challenges for Sun in Ranbaxy deal | Shanghvi, pharma maven with midas touch Economic Times, 1 week ago
Sun Pharma's acquisition of Ranbaxy has once again revived evaluation of the troubled past of the company, that had changed hands merely five years ago. In 2008, when promoters of Ranbaxy announced the sale of India's largest pharmaceutical company ...Business Standard India, 1 week ago
The media and entertainment professionals feel that there is both the need and scope for entrepreneurial leaps and innovative ventures for the sector to grow exponentially. Whether it is the building of a business destination, private equity, ...MyIris, 1 month ago Experts stress on innovation for entertainment sector ProKerala.com, 1 month ago FICCI Frames 2014: Experts stress on innovation for entertainment sector India TV, 1 month ago
More from: , NewKerala.com...and 6 other sources
on your WebpageAdd Widget >Get your members hooked!